文献速递肾小球疾病急性肾损伤遗传性与小管间质肾病

冷纤维蛋白原相关肾病的临床病理谱与治疗结局

Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies.
PubMed 文献 · Kidney Int Rep · 2025-11-05

该回顾性研究在2545例冷纤维蛋白原血症患者中识别出28例(1%)冷纤维蛋白原相关肾病(CFN),表现为寡免疫复合物膜增生性肾小球肾炎或血栓性微血管病,58%的继发性形式伴单克隆丙种球蛋白病。60%患者接受免疫抑制治疗,平均随访476天后65%达到肾脏缓解,基线eGFR较高和使用免疫抑制剂预测缓解。

要点

  • CFN是冷纤维蛋白原血症中极罕见的肾脏表现,患病率约1%。
  • 病理以膜增生性肾小球肾炎为主,常伴血栓和间质免疫浸润。
  • 继发性CFN中单克隆丙种球蛋白病常见,B细胞/浆细胞清除多有效。

核心结论

  • CFN可能是具有肾脏意义的单克隆丙种球蛋白病的一种极罕见且未被充分认识的形式,表现为寡免疫膜增生性肾炎或血栓性微血管病,免疫抑制治疗对多数患者有效。

研究设计与样本

  • 回顾性纳入法国专家实验室诊断冷纤维蛋白原血症且肾活检提示CFN(寡免疫膜增生性肾小球肾炎、血栓性微血管病和/或间接缺血征象)的患者。
  • 共2545例冷纤维蛋白原血症患者中,232例(9%)接受肾活检,仅28例(1%)具有提示CFN的组织学表现。

主要发现

  • AKI占78%,肾病综合征占41%;9例为原发性,19例为继发性。
  • 膜增生性肾小球肾炎最常见,双轨征57%、结节性系膜硬化30%、系膜细胞增生41%、内皮细胞增生56%、新月体/外增生11%、间质免疫浸润41%,血栓占43%。
  • 继发性形式中58%伴单克隆丙种球蛋白病;伴单克隆丙种球蛋白病者皮肤表现(P=0.002)、内皮细胞增生(P=0.002)、间质浸润(P=0.041)和毛细血管血栓(P=0.012)更常见,补体激活有更多趋势(P=0.14)。
  • 60%患者接受不同方案的免疫抑制治疗;平均随访476天(±92)后65%达到肾脏缓解,基线eGFR较高(P=0.04)和使用免疫抑制剂(P=0.03)预测缓解;伴单克隆丙种球蛋白病者中B细胞或浆细胞清除治疗80%有效。

关键数值与推荐

  • 肾脏缓解定义为UPCR降至<0.5 g/g(若基线>3 g/g则下降>50%)且eGFR改善>30%(若基线<60 ml/min/1.73 m2且伴AKI)。

临床怎么用

  • 对冷纤维蛋白原血症患者应警惕CFN,尤其出现AKI、肾病综合征或血栓性微血管病时。
  • 肾活检对诊断CFN至关重要,病理常表现为寡免疫膜增生性肾炎伴血栓。
  • 继发性CFN应筛查单克隆丙种球蛋白病,B细胞或浆细胞清除治疗可能有效。
  • 免疫抑制治疗与肾脏缓解相关,基线eGFR较高者更可能缓解。

局限性

  • 回顾性设计,样本量小(仅28例),随访时间有限。
  • 仅纳入法国专家实验室诊断的冷纤维蛋白原血症患者,可能存在选择偏倚。
  • 免疫抑制治疗方案异质,无法比较不同方案疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cryofibrinogen-associated nephropathy (CFN) is a very rare disease. Only few data are available about the clinicopathological presentation and treatment outcomes. METHODS: Patients with cryofibrinogenemia (CF) diagnosed in French expert laboratories, and kidney biopsy findings suggestive of CFN (pauci-immune membranoproliferative glomerulonephritis [MPGN], thrombotic microangiopathy [TMA] and/or indirect signs of ischemia) were retrospectively included. Estimated glomerular filtration rate (eGFR), urinary protein-to-creatinine ratio (UPCR), and specific treatments were collected. Renal response (RR) was defined as a reduction of UPCR to < 0.5 g/g (or decrease > 50% if > 3 g/g at baseline) and an improvement of eGFR > 30% (if < 60 ml/min per 1.73 m2 and acute kidney injury (AKI) at baseline). RESULTS: Among 2545 patients with CF, 232 (9%) underwent kidney biopsy, and only 28 (1%) had histological findings suggestive of CFN. Ten patients (36%) were female, and median age was 62 (interquartile range [IQR]: 49-71) years. eGFR at diagnosis was 21 (14-44) ml/min per 1.73 m2. Median UPCR was 3.30 (IQR: 1.52-4.85) g/g. AKI (78%) and nephrotic syndrome (41%) were frequent. Nine patients had an essential form, whereas 19 had a secondary form. MPGN was the most frequent pattern, with double contours (57%), nodular mesangial sclerosis (30%), mesangial (41%), endocapillary (56%) and extracapillary (11%) hypercellularity, and interstitial immune infiltration (41%). Thrombi were found in 43% of cases. Strikingly, 58% of the secondary forms were associated with a monoclonal gammopathy (MG). Patients with MG had more frequent skin manifestations (P = 0.002), endocapillary (P = 0.002), interstitial (P = 0.041) infiltration, and capillary thrombi (P = 0.012), and tended to have more frequent complement activation (P = 0.14). Sixty percent of patients were treated with various regimens of immunosuppressants (IS). After a mean follow-up of 476 (± 92) days, 65% of patients had an RR. Higher baseline eGFR (P = 0.04) and use of IS (P = 0.03) were predictive of RR. B-cell or plasma-cell depletion was effective in most cases associated with MG (80%). CONCLUSION: Our study, to the best of our knowledge, described for the first time the prevalence and the clinicopathological spectrum of CFN, which might be a very rare and underrecognized form of MG of renal significance presenting with pauci-immune MPGN ot TMA. IS are effective in most cases.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dang J, Faguer S, Jourde-Chiche N, et al. Clinicopathological Spectrum and Treatment Outcomes of Cryofibrinogen-Associated Nephropathies. Kidney Int Rep. 2025. PMID: 41541779. doi:10.1016/j.ekir.2025.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。